4.8000
-0.3000
(-5.88%)
At close: January 10 at 3:29:02 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
2,000.0000
--
--
--
Operating Expense
45,725.0000
32,740.0000
31,055.0000
23,719.0000
11,400.0000
Operating Income
-45,725.0000
-30,740.0000
-31,055.0000
-23,719.0000
-11,400.0000
Net Non Operating Interest Income Expense
8,207.0000
2,860.0000
553.0000
26.0000
30.0000
Other Income Expense
--
4.0000
3.0000
-749.0000
--
Pretax Income
-37,517.0000
-27,876.0000
-30,499.0000
-24,442.0000
-11,370.0000
Net Income Common Stockholders
-37,517.0000
-27,876.0000
-30,499.0000
-24,442.0000
-11,370.0000
Diluted NI Available to Com Stockholders
-37,517.0000
-27,876.0000
-30,499.0000
-24,442.0000
-11,370.0000
Basic EPS
-0.39
-2.66
-1.38
-1.10
-0.51
Diluted EPS
-0.39
-2.66
-1.38
-1.10
-0.51
Basic Average Shares
29,138.8820
10,460.3350
22,174.0660
22,174.0660
22,174.0660
Diluted Average Shares
32,195.3450
10,460.3350
22,174.0660
22,174.0660
22,174.0660
Total Operating Income as Reported
-45,725.0000
-30,740.0000
-31,055.0000
-23,719.0000
-11,400.0000
Total Expenses
45,725.0000
32,740.0000
31,055.0000
23,719.0000
11,400.0000
Net Income from Continuing & Discontinued Operation
-37,517.0000
-27,876.0000
-30,499.0000
-24,442.0000
-11,370.0000
Normalized Income
-37,518.0000
-27,880.0000
-30,502.0000
-23,693.0000
-11,370.0000
Interest Income
8,207.0000
2,860.0000
553.0000
26.0000
30.0000
Net Interest Income
8,207.0000
2,860.0000
553.0000
26.0000
30.0000
EBIT
-45,725.0000
-30,740.0000
-31,055.0000
-23,719.0000
-11,370.0000
EBITDA
-45,725.0000
-30,740.0000
-31,055.0000
-23,719.0000
-11,370.0000
Net Income from Continuing Operation Net Minority Interest
-37,517.0000
-27,876.0000
-30,499.0000
-24,442.0000
-11,370.0000
Total Unusual Items Excluding Goodwill
1.0000
4.0000
3.0000
-749.0000
--
Total Unusual Items
1.0000
4.0000
3.0000
-749.0000
--
Normalized EBITDA
-45,726.0000
-30,744.0000
-31,058.0000
-22,970.0000
-11,370.0000
12/31/2020 - 7/31/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GX1.F Marker Therapeutics, Inc.
2.6200
0.00%
UTH.F United Therapeutics Corporation
352.30
-0.03%
0A9E.IL CureVac N.V.
4.3740
+1.37%
347850.KQ D&D Pharmatech
53,900.00
-3.92%
MRZM Marizyme, Inc.
0.0041
-14.58%
MAAT.PA MaaT Pharma SA
7.92
-12.78%
NVV1.F Novavax, Inc.
8.89
-6.92%
0QF.DE Moderna, Inc.
41.54
-1.11%
DMYD-B.ST Diamyd Medical AB (publ)
17.14
-5.20%
5CV.F CureVac N.V.
4.1500
+4.27%